ATC code L04
| ATC code L: Antineoplastic and immunomodulating agents |
|---|
| Other ATC codes |
ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup L04 is part of the anatomical group L Antineoplastic and immunomodulating agents.[4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL04.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
L04A Immunosuppressants
[edit]L04AA Selective immunosuppressants
[edit]- L04AA03 Antilymphocyte immunoglobulin (horse)
- L04AA04 Antithymocyte immunoglobulin (rabbit)
- L04AA06 Mycophenolic acid
- L04AA15 Alefacept
- L04AA19 Gusperimus
- L04AA22 Abetimus
- L04AA24 Abatacept
- L04AA28 Belatacept
- L04AA32 Apremilast
- L04AA40 Cladribine
- L04AA41 Imlifidase
- L04AA48 Belumosudil
- L04AA58 Efgartigimod alfa
- L04AA60 Remibrutinib
L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
[edit]- L04AB01 Etanercept
- L04AB02 Infliximab
- L04AB03 Afelimomab
- L04AB04 Adalimumab
- L04AB05 Certolizumab pegol
- L04AB06 Golimumab
- L04AB07 Opinercept
L04AC Interleukin inhibitors
[edit]- L04AC01 Daclizumab
- L04AC02 Basiliximab
- L04AC03 Anakinra
- L04AC04 Rilonacept
- L04AC05 Ustekinumab
- L04AC07 Tocilizumab
- L04AC08 Canakinumab
- L04AC09 Briakinumab
- L04AC10 Secukinumab
- L04AC11 Siltuximab
- L04AC12 Brodalumab
- L04AC13 Ixekizumab
- L04AC14 Sarilumab
- L04AC15 Sirukumab
- L04AC16 Guselkumab
- L04AC17 Tildrakizumab
- L04AC18 Risankizumab
- L04AC19 Satralizumab
- L04AC20 Netakimab
- L04AC21 Bimekizumab
- L04AC22 Spesolimab
- L04AC23 Olokizumab
- L04AC26 Goflikicept
L04AD Calcineurin inhibitors
[edit]- L04AD01 Ciclosporin
- L04AD02 Tacrolimus
- L04AD03 Voclosporin
L04AE Sphingosine 1-phosphate (S1P) receptor modulators
[edit]- L04AE01 Fingolimod
- L04AE02 Ozanimod
- L04AE03 Siponimod
- L04AE04 Ponesimod
- L04AE05 Etrasimod
L04AF Janus-associated kinase (JAK) inhibitors
[edit]- L04AF01 Tofacitinib
- L04AF02 Baricitinib
- L04AF03 Upadacitinib
- L04AF04 Filgotinib
- L04AF05 Itacitinib
- L04AF06 Peficitinib
- L04AF07 Deucravacitinib
- L04AF08 Ritlecitinib
L04AG Monoclonal antibodies
[edit]- L04AG01 Muromonab-CD3
- L04AG02 Efalizumab
- L04AG03 Natalizumab
- L04AG04 Belimumab
- L04AG05 Vedolizumab
- L04AG06 Alemtuzumab
- L04AG07 Begelomab
- L04AG08 Ocrelizumab
- L04AG09 Emapalumab
- L04AG10 Inebilizumab
- L04AG11 Anifrolumab
- L04AG12 Ofatumumab
- L04AG13 Teprotumumab
- L04AG14 Ublituximab
- L04AG15 Divozilimab
- L04AG16 Rozanolixizumab
- L04AG17 Seniprutug
L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
[edit]- L04AH01 Sirolimus
- L04AH02 Everolimus
L04AJ Complement inhibitors
[edit]- L04AJ01 Eculizumab
- L04AJ02 Ravulizumab
- L04AJ03 Pegcetacoplan
- L04AJ04 Sutimlimab
- L04AJ05 Avacopan
- L04AJ06 Zilucoplan
- L04AJ07 Crovalimab
- L04AJ08 Iptacopan
- L04AJ09 Danicopan
- L04AJ10 Vilobelimab
- L04AJ11 Pozelimab
L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors
[edit]- L04AK01 Leflunomide
- L04AK02 Teriflunomide
L04AX Other immunosuppressants
[edit]- L04AX01 Azathioprine
- L04AX02 Thalidomide
- L04AX03 Methotrexate
- L04AX04 Lenalidomide
- L04AX05 Pirfenidone
- L04AX06 Pomalidomide
- L04AX07 Dimethyl fumarate
- L04AX08 Darvadstrocel
- L04AX09 Diroximel fumarate
- L04AX10 Tegomil fumarate
References
[edit]- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code L04". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QL04". WHO Collaborating Centre for Drug Statistics Methodology.